Table 2.

Univariate analysis

Outcomes	Cy TBI Probability (95% CI)	Oral BuCy Probability (95% CI)	IV BuCy Probability (95% CI)	Overall p- values
Neutrophil recovery
NEval	222	354	97
@ 28 days	92 (88-95)	91 (88-94)	95 (90-98)	0.391
Platelet recovery
NEval	221	346	96
@ 28 days	64 (58-70)	75 (71-80)	77 (68-85)	0.009
@ 100 days	90 (85-93)	93 (90-95)	96 (91-99)	0.103
Acute GVHD (II-IV)
NEval	222	352	97
@ 100 days	56 (50-63)	43 (39-49)	46 (37-56)	0.014
Acute GVHD (III-IV)
NEval	222	354	97
@ 100 days	24 (19-30)	20 (16-24)	26 (18-35)	0.290
Hepatic Veno-occlusive Disease
NEval	222	354	97
@ 100 days	5 (2-9)	9 (7-13)	6 (2-12)	0.17
Interstitial Pneumonia
NEval	222	354	97
@ 100 days	9 (5-13)	5 (3-8)	4 (1-9)	0.22
Chronic GVHD
NEval	216	348	95
@ 5 years	55 (48-61)	62 (57-68)	67 (57-76)	0.082
Non-relapse mortality
NEval	216	350	95
@ 1 year	25 (20-31)	20 (16-24)	16 (9-24)	0.142
@ 3 years	31 (25-38)	24 (20-29)	22 (14-31)	0.139
@ 5 years	31 (25-38)	25 (21-30)	36 (25-48)	0.119
Relapse
NEval	216	350	95
@ 5 years	17 (12-23)	17 (12-22)	7 (2-14)	0.014
Leukemia free survival
NEval	216	350	95	0.102
@ 1 year	67 (60-73)	74 (69-78)	80 (72-88)	0.031
@ 3 years	55 (48-62)	62 (57-68)	74 (64-82)	0.006
@ 5 years	52 (45-59)	58 (52-64)	57 (45-69)	0.384
Overall survival
NEval	222	354	97	0.196
@ 1 year	74 (68-80)	80 (75-84)	84 (76-91)	0.118
@ 3 years	67 (60-73)	74 (69-78)	77 (68-85)	0.097
@ 5 years	66 (59-72)	72 (67-77)	61 (50-73)	0.152

N Eval indicates number evaluable; Cy, cyclophosphamide; TBI, total body irradiation; IV, intravenous; Bu, busulfan, GvHD, graft versus host disease